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CHAPTER 1. GENERAL INTRODUCTION 
Thesis Organization 
This thesis is written using the alternate format, and it includes a general 
introduction to the research problem, a literature review regarding the pathogenesis 
and vaccinology of Streptococcus suis, two manuscripts concerning S. suis, and a 
final chapter that summarizes the research and discusses the contributions to 
knowledge regarding S. suis treatment and prevention. One manuscript has been 
published, and one has been submitted for publication. The references cited in each 
chapter are located immediately after each chapter. 
Statement of the Problem and Research Summary 
Streptococcus suis (S. suis) is a ubiquitous gram positive streptococcus found 
in swine throughout the world and commonly causes septicemia, arthritis, meningitis, 
and has been reported to be an important cause of pneumonia in young pigs4 ·5. 
Piglets are colonized shortly after birth with multiple serotypes from excretions and 
secretions from the dam 1. Segregated early weaning and medicated early weaning 
protocols have failed to eliminate or reduce the incidence of the disease in modern 
swine operations and may contribute to the increased prevalence of the disease9. 
When pigs are coinfected with porcine reproductive and respiratory syndrome virus 
(PRRSV), S. suis mortality among young pigs may reach 15% 9. Coinfection is 
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common and especially problematic. PRRSV may affect any age pig causing 
reproductive failure in sexually mature pigs and respiratory disease in pigs of all 
ages7• Vaccination protocols for PRRSV commonly fail to control the disease and 
methods to control S. suis have shown limited success3·6. A challenge model to 
study the interactions of these swine pathogens has been developed8 and is used in 
this research to evaluate the efficacy of various antimicrobial treatment protocols 
and vaccination regimens for both PRRSV and S. suis. 
When tested in the PRRSV/S. suis coinfection model, antimicrobial therapy 
with ceftiofur hydrochloride (Excenel®) when given for three consecutive days post 
S. suis infection is the only treatment that has successfully reduced mortality 
associated with PRRSV/S. suis coinfection. Treatment with other commonly used 
antimicrobials failed to reduce mortality associated with PRRSV/S. suis coinfection. 
Treatments that failed in our model presented in this thesis included ampicillin given 
for three consecutive days post S. suis infection, and ceftiofur hydrochloride given 
every third day for three treatments post S. suis infection. Previous work has also 
shown other commonly used treatments have failed to significantly reduce mortality 
associated with PRRSV/S. suis coinfection2·3. Those treatments included: procaine 
penicillin G for three consecutive days post S. suis infection and tiamulin given per 
os in drinking water for three days post S. suis infection. 
Considerable research has been conducted to create a successful prevention 
method to prevent mortality associated with PRRSV/S. suis coinfection. Vaccines to 
date do not provide complete protection against S. suis or PRRSV. In this work and 
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in previous work2•3, two commercial PRRSV vaccines have failed to prevent mortality 
associated with PRRSV/S. suis coinfection. 
In chapter 3 we describe research in which a significant reduction in mortality 
was achieved by exposing pigs prior to PRRSV challenge to a reduced dose S. suis 
exposure. There was however, residual virulence associated with reduced dose live 
vaccine. In chapter 4 we describe work where a reduction in mortality (p=0.06) was 
observed when nursery pigs were vaccinated with a ceftiofur killed bacterin 
intranasally and intramuscularly, but this did not reach a significant (p<0.05) level. 
Vaccines that failed to induce any observable reduction in clinical signs, gross and 
microscopic lesions, and mortality included two conventional S. suis vaccines, a 
commercial S. suis vaccine and an autogenous S. suis bacterin, and two 
experimental S. suis vaccines (a capsular polysaccharide conjugate vaccine and a 
streptomycin dependent mutant of the parent strain). The development of these 
vaccines is discussed in chapter 4. 
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CHAPTER 2. LITERATURE REVIEW 
Virulence Factors, Pathogenesis, and Clinical Syndromes 
Associated with S. suis Infection 
Streptococci are Gram positive chaining bacteria that are facultative 
anaerobes20. Streptococcus suis (S. suis) commonly colonizes pigs within a short 
period of time post partum3. Virulent strains of S. suis commonly induce meningitis, 
arthritis, and polyserositis in nursery age pigs28. There have been 35 serotypes of S. 
suis identified35. S. suis serotype 2 is the most common serotype isolated from 
diseased pigs at the Iowa State University Veterinary Diagnostic Laboratory (ISU-
VDL) (Schmitt, unpublished data). Isolations of S. suis are on the rise at the ISU-
VDL as are coinfections with viral agents such as porcine reproductive and 
respiratory syndrome virus (PRRSV) (Figure 1 ). S. suis serotype 2 is also the 
predominant serotype that causes septicemia, meningitis and endocarditis in 
humans 13. S. suis uses many virulence factors to colonize and infect the host. 
Virulence factors include the capsule, a thiol-activated hemolysin, extracellular factor 
(EF) and muramidase-released protein (MRP)5. 
The capsule of S. suis serotype 2 is composed of sialic acid and other 
sugars7. Sialic acid is used by many bacterial species as an antiphagocytic factor 
that inhibits the activation of the alternative complement cascade7. Sialic acid's 
purpose in the capsule is unknown but does not seem to be critically necessary 
when comparing virulent and avirulent strains; however, it may play a role in 
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facilitating intracellular survival rather than prevention of phagocytosis7• Surface 
characteristics of the organism may change when the organism is in different 
environments. Isolates grown in media containing fetal calf serum have been shown 
to produce more capsular material than those cultured in media without fetal calf 
serum40. Streptococcus pneumoniae is protected from leukocytes by its capsule and 
mutants deficient in capsular material elicit a severe inflammatory response35. 
Production of capsular material may depend on the site of S. suis colonization within 
the body. The mechanisms for regulation of capsule production in S. suis are 
unknown. However, the necessity of the capsule for survival in the host has been 
demonstrated8. Capsule deficient mutants were isolated and survival was monitored 
after challenge in mice. Mice challenged with capsule deficient mutants survived at 
a significantly higher rate than those challenged with wild type strains. Capsule 
expression by S. suis is reduced in vitro when compared to in vivo isolation and 
characterization7•19. Experiments have shown that an increased amount of capsule 
is produced when the organism is placed in the abdomen of rats 19. Virulent strains 
show an increased resistance to killing by porcine neutrophils or murine 
macrophages when their capsule is thicker4•19. 
The hemolysin (suilysin) produced by S. suis has been classified into the 
thiol-activated hemolysin group 14. Activity is reduced when the molecule becomes 
oxidized14. Many other pathogens utilize a hemolysin in their pathogenesis including 
S. pyogenes, group B streptococci, group C streptococci, group G streptococci, S. 
pneumoniae, Escherichia coli, Listeria monocytogenes, Mannheimia (Pasture/la) 
haemolytica, and Actinobacillus pleuropneumoniae11 •14• Suilysin is inhibited by 
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cholesterol and is produced in late log phase of culture 11 . No significant anti-suilysin 
titer elevation has been observed in challenged pigs 11, though the suilysin appears 
to enhance the ability of the organism to invade epithelial cells 18. Protection has 
been reported when pigs are vaccinated with hemolysin from S. suis15. In this work 
three groups of pigs were vaccinated with either purified suilysin, other extracellular 
antigens free of suilysin, or a placebo. After intravenous challenge with the parent 
strain, pigs in the group vaccinated with the purified suilysin showed reduced clinical 
signs and lesions 15. 
Two proteins have been identified as being associated with virulence of S. 
suis by analyzing protein profiles of pathogenic and non-pathogenic S. suis 
isolates38. These proteins were muramidase-related protein (MRP) and extracellular 
factor (EF). The MRP is a 136 kDa cell wall-associated protein and the EF is a 110 
kDa extracellular protein. Through the 1990's S. suis strains have been 
characterized based upon their ability to produce MRP and EF as a possible link to 
virulence 10. Isolates that were MRP+ and EF+ were considered highly virulent, 
those with MRP+ EF- or MRP- EF- were considered moderately virulent to 
avirulent10. Studies of United States S. suis isolates do not show these trends as 
seen in European isolates 10. To date the genes have been sequenced, cloned, and 
mutants experimentally inoculated into pigs. These mutants have shown equivocal 
results29·30. 
The complete pathogenesis of S. suis remains a mystery, but a recent 
manuscript12 summarizes information from many sources and gives a basic 
framework for understanding. S. suis colonizes the oropharynx and tonsils early in 
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life3·12 . Coinfection with other agents, primarily viral respiratory pathogens, such as 
porcine reproductive and respiratory syndrome virus (PRRSV), appear to play a role 
in the development of disease. Effects of such viral infections have been 
described33 . PRRSV infects cells of monocyte-derived lineage and decreases their 
bactericidal activity through reduction in production of superoxide anion and 
myeloperoxidase -H20 2-halide system33 . 
Recent data suggests that encapsulated strains of S. suis are not ingested by 
murine macrophages as efficiently as group B Streptococcus type Ill (GBS)26. This 
avoidance of phagocytosis is discussed in the following paragraphs. 
Virulent isolates utilizing the thiol-activated hemolysin and various virulence 
factors are capable of epithelial invasion 12·18. Virulence has been correlated with 
possession of the genes encoding suilysin, MRP and EF12·31 . Once the epithelial 
barrier is breached the organism is opsonized and phagocytosed, presumably by 
PMN's. Sialic acid does not seem to interfere with opsonization and phagocytosis7. 
Recent work by Brown suggests the presence of a neutrophil suppressive factor 
which acts to decrease degranulation into phagosomes5. S. suis then may lyse the 
phagocyte or exit the cell by an unknown pathway and colonize any preferred site of 
the body, namely meningeal, pleural, peritoneal, and pericardia! spaces, and blood . 
Colonization of internal tissues with S. suis results in a massive influx of 
PMN's and inflammatory mediators. These inflammatory mediators cause loss of 
function of various organs and organ systems. Suggested access sites to the 
cerebrospinal fluid include dural venous sinuses, leptomeningeal blood vessels, the 
choroid plexus, and direct meningeal trauma41 . Carriage by macrophages has also 
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been suggested as a possible mechanism for access to the cerebrospinal fluid41 • 
Access to serosal surfaces is believed to be through similar mechanisms, but 
primarily by carriage within a leukocyte. 
Successful Vaccine Approaches to Organisms with Related 
Pathogenesis 
Human neonatal meningitis may be caused by a number of organisms 
including: Haemophilus influenzae, Neisseria meningitidis, and Streptococcus 
pneumoniae21 • Streptococcus suis is a common cause of neonatal meningitis, 
bacteremia, arthritis, and polyserositis in swine. Several similarities exist between 
these organisms including capsular composition and hemolysin production. 
Immunity has proven to be difficult to generate in newborns due to limited 
immunocompetence early in life and maternal antibody interference with vaccines. 
Recently dramatic improvements have been developed in human meningitis 
vaccines. Vaccination with conjugated capsular material from the human meningitis-
causing organisms to proteins has been shown to deliver high levels of protection 
against Haemophi/us influenzae type b and S. pneumoniae24·27 . Research 
presented in Chapter 3 of this thesis discusses attempts at formulation and 
description of efficacy of a S. suis capsular polysaccharide conjugate vaccine. 
Vaccination protocols for infants include vaccination for H. influenzae type b 
and S. pneumoniae at 2, 4, and 6 months of age and a booster at 12-15 months with 
a capsular polysaccharide conjugate vaccine 1·2. Currently licensed H. influenzae 
11 
type b vaccines include: ActHIB™ (Pasteur Merieux Vaccins), OmniHIB™ (Pasteur 
Merieux Vaccins), Tetramune™ (Lederle Laboratories/Praxis Biologics), ProHIBiT® 
(Connaught), PedvaxHIB® (Merck Sharp and Dahme) and HibTITER® (Lederle 
Laboratories/Praxis Biologics)8 . Currently licensed S. pneumoniae vaccines include: 
Prevnar™ (Lederle Laboratories) and Pneumovax® 23 (Merck and Co.)8. Currently 
only Aventis Pasteur holds a license for N. meningitidis vaccines8. 
In 1988 one in 200 children under the age of 5 developed meningitis caused 
by H. influenzae type b24. Current data shows a 99% reduction in cases between 
1988 and 199624• Early data from the heptavalent pneumococcal vaccine indicate 
that it has the potential to reduce bacteremia, meningitis, and otitis media by 85, 83, 
and 65% respectively27• There is no trend data yet available for the N. meningitidis 
vaccine. 
All of these vaccines currently produced for prevention of meningitis in infants 
are capsular polysaccharide conjugates. Covalent coupling of a capsular 
polysaccharide to a T cell dependent (TD) protein substantially enhanced the 
immunologic response to the antigen 1• Without conjugation, capsular 
polysaccharide from meningitis causing organisms is considered T cell independent 
(Tl). Comparisons of immune responses to conjugated versus unconjugated 
vaccines show that antibody isotypes are changed9 . Exposure to unconjugated 
capsular polysaccharide initiates primarily an lgM and lgG3 response in mice9. 
These are isotypes usually produced during a primary immune response9. 
Conjugated capsular polysaccharide induces primarily an lgG1 response9. Other 
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work has reported that there is variation in immunogenicity among serotype 
conjugates in multivalent S. pneumoniae vaccines 17. 
Mechanistically, differences in immune responses between conjugated and 
non-conjugated capsular polysaccharide relate to the use of the exogenous pathway 
for antigen recognition. A specific B cell clone recognizes conjugated capsular 
polysaccharide. The entire antigen (both polysaccharide and protein moiety) is 
internalized. Once internalized, it is degraded and portions of the protein moiety are 
displayed on the surface of the cell via an MHC class 2 molecule. T helper cells 
specific for the protein moiety bind the cell and stimulate the B cell to switch antibody 
classes and undergo clonal expansion34• Immune responses to unconjugated 
capsular polysaccharide are much less complex. A specific B cell clone recognizes 
the capsular material, but it has no protein moiety to express to a helper T cell, thus 
it does not become stimulated to undergo antibody class switching and clonal 
expansion. 
Attenuated strains of organisms have been used for many years to ·induce an 
immune response34. In the 1930's Dr. John Buck isolated a temperature sensitive 
Bruce/la abortus strain that was used until recently. Strain 19 was mistakenly left at 
room temperature for a year and then subcultured. It was found to be avirulent and 
yet provide a protective immune response. Further work has resulted in a rough 
Bruce/la abortus mutant that is now the standard for vaccination against this 
disease. This vaccine, named RB51, is rifampin resistant and was created by serial 
passage of a virulent B. abortus strain on standard plates25. 
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Nutrient dependent strains work via a similar principle. Culturing an organism 
in a unique environment and allowing them to mutate and adapt to those conditions 
leads to dependence on those conditions. Spontaneous mutagenesis may take 
considerable time. Utilizing mutagenic agents to create genetic variation increases 
the chance of isolating strains with ideal genetic variation. Selection for those 
genetic variabilities is then easily accomplished using specific growth conditions. In 
chapter 3, selection of a streptomycin dependent strain of S. suis is discussed. 
· Currently, the Bayer Corporation makes a vaccine using this same principle for the 
vaccination of healthy cattle against respiratory disease caused by Pasture/la 
multocida and Mannheimia (Pasture/la) haemolytica. 
Streptococcus equi is a beta-hemolytic streptococcus classified in Lancefield 
group C20 . It is different from S. suis in that it produces an M protein on it's surface. 
Vaccine development has centered on generating mucosa! antibody (lgA) against 
this protein. There has been limited success of vaccines against the M protein to 
date. Recent research has focused on generating mucosa! immunity with 
recombinant products32 . In chapter 3, use of a killed S. suis product intranasally to 
stimulate a mucosa! immune response is discussed. The S. equi M protein has 
been transformed into Escherichia coli BL21 and Salmonella typhimurium MGN707 
(attenuated strain) and expressed. Strong mucosa! and humoral antibody 
production has been measured when the recombinant Salmonella strain was given 
intranasally32. 
A Salmonella choleraesuis var. kuzendorf modified live vaccine is now 
marketed by Boehringer lngelheim Vetmedica, Inc. The vaccine was produced by 
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serial passage through porcine neutrophils23 . After serial passage through porcine 
neutrophils, the organism had increased resistance to killing by porcine neutrophils 
and had been. cured of a 50 kb plasmid23 . Results of field trials indicate a significant 
reduction of disease induced by the modified live organism in vaccinated pigs versus 
non vaccinates22. The mechanism of attenuation has not been fully elucidated, but it 
is suspected that by mimicking the host's immune system through serial neutrophil 
passage the organism has undergone genetic changes that have rendered it 
avirulent23. 
A Lawsonia intracel/ularis modified live vaccine is now marketed by 
Boehringer lngelheim Vetmedica, Inc. for use in swine. The vaccine was produced 
by serial passage of a virulent isolate on McCoy (ATCC 1696) cells37• It is delivered 
orally in the drinking water. The organism has shown efficacy in reducing L. 
intracel/ularis colonization of the ileum, reduction of gross and microscopic lesions, 
reduced fecal shedding of the organism, and improved weight gain 16. 
A modified live Actinobacillus pleuropneumoniae vaccine is now marketed by 
Boehringer lngelheim Vetmedica, Inc. for use in swine for protection against multiple 
serotypes. The organism is an attenuated capsule-deficient non-typeable strain. 
The Actinobacil/us pleuropneumoniae vaccine strain was produced by 
electroporation of a plasmid construct containing genes necessary for the production 
of serotype 5 into a serotype 1 organism39. This addition of genes causes less 
capsular material to be produced and renders the organism non-typeable. Low 
levels of serotype 1 and serotype 5 capsular material are produced, but is 
significantly (P<0.05) lower than either parent strain39. The vaccine has been tested 
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against homologous and heterologous challenge and has shown adequate 
protection. The vaccine is delivered intramuscularly in the neck in pigs six weeks of 
age or older. Label indications warn of 100% lethargy post vaccination, 20% 
vomiting, and some injection site swelling. 
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CHAPTER 3. INFLUENCE OF AMPICILLIN, CEFTIOFUR, 
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Abstract 
The objective of this research was to evaluate the efficacy of two 
antimicrobials (ampicillin and ceftiofur), a modified-live porcine reproductive and 
respiratory syndrome virus (PRRSV) vaccine, and low dose exposure to 
Streptococcus suis (S. suis) on disease associated with PRRSV/S. suis coinfection. 
Fifty-six, crossbred, PRRSV-free pigs were weaned at 10-12 days of age and 
randomly assigned to five treatment groups. All pigs were inoculated with 2 ml 106.4 
TCID50/ml of high virulence PRRSV isolate VR-2385 intranasally at 29-31 days of 
age (day 0 of the study) followed 7 days later by intranasal inoculation with 2 ml 108·9 
CFU/ml S. suis type 2 isolate ISU VOL #40634/94. Pigs in group 1 (n=10) served as 
untreated positive controls. Pigs in group 2 (n=12) were treated with 5.0 mg/kg 
ceftiofur hydrochloride intramuscularly (IM) on days 8, 11, and 14. Pigs in group 3 
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(n=11) were treated with 11 mg/kg ampicillin IM on days 8, 9, and 10. Pigs in group 
4 (n=12) were vaccinated 14 days prior to PRRSV challenge with a commercial 
modified-live PRRSV vaccine. Pigs in group 5 (n=11) were exposed to a 1: 100 
dilution of the S. suis challenge inoculum 19 days prior to S. suis challenge. 
Mortality was 80, 25, 82, 83, and 36% in groups 1-5, respectively. The S. ·suis 
exposure had some residual virulence, evidenced by S. suis induced meningitis in 2 
pigs prior to challenge. Treatment with ceftiofur hydrochloride and reduced dose 
exposure to S. suis were the only treatments which significantly (P<0.05) reduced 
mortality associated with PRRSV/S. suis coinfection. Treatment with ceftiofur 
hydrochloride and exposure to S. suis both significantly (P<0.05) reduced recovery 
of S. suis from tissues at necropsy, and significantly (P<0.05) reduced the severity of 
gross lung lesions. 
Introduction 
PRRSV and S. suis coinfection continues to be a major problem facing swine 
producers2•12 . Case trends at the Iowa State University Veterinary Diagnostic 
Laboratory (ISU-VDL) indicate a 3-fold increase in the number of S. suis cases, a 7-
fold increase in PRRSV cases, and a 9-fold increase in the number of PRRSV/S. 
suis coinfection cases in the last five years. As the trends suggest, common 
prevention and treatment protocols often fail emphasizing the need for more 
efficacious treatment and control regimens. In previous work we demonstrated that 
treatment with ceftiofur hydrochloride on days 1, 2, and 3 post S. suis challenge (10, 
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11, and 12 days post PRRSV challenge) significantly (P<0.05) reduced mortality 
(from 63% to 9%) associated with PRRSV/S. suis coinfection. Penicillin and tiamulin 
treatment, vaccination with a commercially available modified live PRRSV vaccine, 
or vaccination with 2 doses of a killed S. suis bacterin failed to significantly (P<0.05) 
reduce mortality associated with PRRSV/S. suis coinfection6. This experiment was 
designed to evaluate the efficacy of a modified ceftiofur hydrochloride treatment 
regimen, intramuscular treatment with ampicillin, a second modified-live PRRSV 
vaccine, and reduced dose exposure to S. suis. Antimicrobial treatments and 
PRRSV vaccination protocols were chosen based on protocols commonly reported 
on ISU-VDL submission forms and discussions with swine veterinarians in the field. 
The reduced dose S. suis exposure protocol further elucidates a similar field trial13 in 
a controlled exposure situation. 
Materials and Methods 
Experimental Design 
Fifty-six, crossbred, PRRSV-negative pigs were weaned at 10-12 days of age 
and moved to the research facility at Iowa State University. The pigs were randomly 
assigned to 5 treatment groups of 10-12 pigs each, injected with 5.0 mg/kg ceftiofur 
hydrochloride intramuscularly (IM) once per day for the first three days, and allowed 
to acclimate for three weeks. All pigs received 2 ml 106.4 tissue culture infective 
dose (TCID50)/ml high virulence PRRSV isolate VR-2385 intranasally on day 0 of the 
trial (0 days post infection or DPI), and 2 ml 108·9 colony forming units (CFU)/ml S. 
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suis serotype 2 isolate ISU-VDL #40634/94 intranasally on day 7 of the trial. 
Treatment groups are summarized in Table 1. 
lnocula Preparation 
PRRS challenge virus isolate VR-2385 was propagated on MARC-145 
cells and titrated by serial 10-fold dilutions in 96-well microtiter plate as 
previously described6. The challenge virus had a titer of 106.4 TCID50/ml and was 
at the ?1h passage in cell culture. 
Streptococcus suis serotype 2, isolate ISU VDL #40634/94, was prepared 
and delivered as previously described6. A challenge dose of 2 ml at 108·9 CFU/ml 
was used. A sample of the inoculum was tested for purity by plating a sample onto a 
blood agar plate (BAP) and growing it overnight at 37°C in 5% C02 air. 
The challenge inoculum was tested for antimicrobial susceptibility to ceftiofur 
and ampicillin using an in vitro microbroth dilution determination of the minimum 
inhibitory concentration (MIC) (Trek Diagnostic Systems, Inc., Westlake, Ohio, USA). 
The isolate was susceptible to ceftiofur at 0.50 µg/ml, and ampicillin at 0.12 µg/ml. 
Clinical Evaluation 
Rectal temperatures, clinical respiratory disease scores, clinical lameness 
scores and central nervous system (CNS) scores were recorded daily as previously 
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described6. Pigs found dead were not scored for that day and pigs that w~re 
euthanitized or found dead were not scored for the remainder of the study. 
Necropsy 
Pigs exhibiting moderate to severe CNS disease (opisthotonous, paddling, 
prostration, or ataxia) and/or those that were recumbent due to severe joint swelling 
and lameness were immediately euthanitized and necropsied. All pigs that survived 
the co infection were euthanitized and necropsied on day 28 of the study. A score for 
the percent of the lung with macroscopically visible pneumonia was given to 
estimate the amount of PRRSV-induced pneumonia (scores range from 0-100%) as 
previously described4•5. Sections for histopathologic examination were taken from 
brain , lung, any swollen joint (or left hock if no joint swelling was observed), lymph 
nodes, tonsil , liver, spleen, heart, kidney, ileum, and nasal turbinate. 
Serology and Virus Isolation 
Blood samples for serology were collected from all animals two days after 
arrival (-17 DPI) at the research facility and at 0 DPI, the day of PRRSV challenge. 
Serum antibody to PRRSV was measured using Herd Check PRRSV ELISA (IDEXX 
Laboratories, Westbrook, Massachusetts, USA). Animals with an S/P ratio of >0.4 
were considered positive. 
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Blood samples for virus isolation were collected from all animals on days 0, 7, 
14, 21 and the day of necropsy. Bronchoalveolar lavage (BAL) was aseptically 
performed on all pigs at necropsy using 25 ml minimal essential medium. PRRSV 
isolation was performed on serum and BAL samples by inoculation of MARC-145 
cells as previously described11. An indirect immunofluorescence assay8 using an 
anti-PRRSV monoclonal antibody SDOW-179 and FITC-conjugated antimouse lgG 
(Sigma, St. Louis, Missouri, USA) was used to confirm viral cytopathic effect (CPE). 
S. suis Isolation and Identification 
Whole blood was collected from group 5 (reduced dose S. suis exposure) and 
cultured prior to (-12 DPI) and 2 days after exposure (-10 DPI). Whole blood was 
also collected and cultured prior to S. suis challenge, 2 days after S. suis challenge, 
and at necropsy from all pigs in groups 1-5. The serosal surfaces (pleura, 
pericardium and peritoneum), BAL fluid , any swollen joints (or the left hock if no joint 
swelling was observed), and meninges were swabbed and plated for bacterial 
identification at the time of necropsy. Colonies that exhibited alpha hemolysis and 
were characteristic of streptococci on blood agar were subcultured and tested for 
amylase production and growth in 6.5% NaCl brain heart infusion (BHI) broth3. S. 
suis isolates were serotyped by coagglutination7• 
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Statistical Analysis 
Fisher's Exact test was used to analyze mortality and organism isolation data 
with P<0.05 used as the level of significance. Clinical scores, and macroscopic and 
microscopic lesion scores were evaluated by analysis of variance (ANOVA) using a 
completely randomized design with the pig as the experimental unit. If the overall 
ANOVA was significant (P<0.05), pair wise comparisons were performed by least 
significant difference. 
Results 
Clinical Evaluation 
Pigs in group 1 (untreated positive controls) exhibited CNS disease, 
lameness, elevated rectal temperatures (>40°C), and respiratory distress from 1-21 
DPI. Forty-eight hours after S. suis challenge, 4/10 of pigs exhibited lameness and 
72 hours post challenge 8/10 pigs exhibited moderate to severe CNS signs. Overall 
mortality in this group was 80% (Figure 1 ). 
Pigs in group 2 (ceftiofur hydrochloride treatment on 8, 11, and 14 DPI) 
showed the fewest clinical signs and had the lowest mortality of any group in the 
study. Five days after S. suis challenge, 9/12 pigs exhibited mild lameness. 
Elevated rectal temperatures and respiratory distress was observed in this group 
similar to the positive controls. At 18 DPI (4 days after the final treatment of 
ceftiofur) one pig in this group exhibited swollen joints and severe lameness. Three 
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pigs were necropsied between 18 DPI and 24 DPI due to CNS signs and/or 
lameness. Overall mortality in this group was 25% (Figure 1 ). 
Pigs in group 3 (ampicillin treatment on 8, 9, and 10 DPI) exhibited clinical 
signs similar to those observed in the positive control group; however, the signs 
were delayed in onset. Pigs in this group were active and exhibited no lameness 
until 24 hours after ampicillin treatment was stopped (11 DPI) when 5/11 pigs 
exhibited mild to moderate lameness. Forty-eight hours after treatment was stopped 
all pigs in this group exhibited mild to moderate lameness. Mortality mimicked the 
positive controls but had a 3 day delay in onset. Overall mortality in this group was 
82% (Figure 1 ). 
Pigs in group 4 (modified live PRRSV vaccine) exhibited mild respiratory 
distress on days 4-6 post vaccination. They had significantly (P<0.05) reduced 
rectal temperatures after PRRSV challenge but after S. suis challenge the group 
mean rectal temperatures were comparable to the positive controls. This group also 
had a significant (P<0.05) decrease in clinical respiratory scores prior to S. suis 
challenge, but clinical respiratory scores rose to a level comparable to that of the 
positive controls following S. suis challenge. Eight of twelve pigs in this group were 
necropsied within 7 days of S. suis challenge due to CNS signs and lameness. 
Overall mortality in this group was 83% (Figure 1 ). 
Pigs in group 5 were exposed 12 days prior to PRRSV challenge (19 days 
prior to S. suis challenge) with a 1: 100 dilution of the S. suis challenge inoculum. By 
4 days following the reduced dose S . suis exposure, this group was lethargic as a 
whole, had roughened hair coats, and reduced feed consumption. By nine days 
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after exposure, 3/11 pigs exhibited mild lameness. Two of the eleven pigs of this 
group exhibited ataxia, recumbancy, head tilt, and elevated rectal temperatures 
(>40°C) between -6 and 0 DPI. These two pigs were euthanitized and necropsied. 
Ofthe remaining nine pigs, two more died between 6-8 days following S. suis 
challenge. Overall mortality in this group was 36% (Figure 1 ). 
Gross and Microscopic Lesions 
Gross lung lesions associated with PRRSV infection were characterized by 
mottled-tan rubbery lungs that fail to collapse. The untreated positive controls 
(group 1) had a mean gross lung lesion score of 40%. Mean gross lung lesion 
scores in groups 2-5 were 13, 29, 20, and 12%, respectively. Ceftiofur treatment 
(group 2), vaccination with the modified live PRRSV vaccine (group 4) and exposure 
to S. suis (group 5) significantly (P<0.05) reduced the severity of gross lung lesions. 
Other gross lesions observed included suppurative meningitis in 3/10, 4/11, and 4/12 
pigs in groups 1, 3, and 4, respectively. Fibrinosuppurative arthritis was observed in 
8/10, 5/12, 5/11, 7/12, and 3/11 pigs in groups 1-5, respectively. Fibrinosuppurative 
polyserositis was observed in 3/10, 2/12, 6/11, 7 /12, and 6/11 pigs in groups 1-5, 
respectively. 
Microscopic lesions observed were similar among groups. All pigs had 
evidence of moderate to severe proliferative interstitial pneumonia characteristic of 
PRRSV4·5. Other microscopic lesions observed included nonsuppurative 
encephalitis, fibrinosuppurative and histiocytic meningitis, fibrinosuppurative 
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synovitis, follicular hyperplasia of lymph nodes and tonsil , polyserositis, and 
suppurative bronchopneumonia as seen before with this model6. 
Serology and Virus Isolation 
PRRSV was isolated from bronchoalveolar lavage samples of all pigs in all 
groups at necropsy. PRRSV was also isolated from serum from all pigs on days 7, 
14, and 21 post PRRSV challenge and at necropsy. All pigs were serologically 
negative for PRRSV antibody upon arrival and only pigs in group 4 (modified live 
PRRSV vaccine) were seropositive prior to PRRSV challenge. All pigs were 
serologically positive for PRRSV on days 7, 14, and 21 post PRRSV challenge. 
Bacteriology 
S. suis recovery is summarized in Table 2. We failed to recover 
Haemophilous parasuis or Actinobacil/us suis from any of the pigs. S. suis was 
recovered from significantly (P<0.05) fewer pigs in groups 2 and 5 than in groups 3 
and 4. S. suis was also recovered from the meninges of significantly (P<0.05) more 
pigs in group 4 (modified-live PRRSV vaccine) than from the meninges of pigs in 
groups 2 and 5. 
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Discussion 
This PRRSV/S. suis coinfection model represents a severe challenge that 
consistently induces 60-80% mortality in the untreated positive controls and provides 
an excellent model to test treatment and vaccination protocols. Unlike field 
conditions, use of the coinfection model has the advantage of knowing when all the 
pigs in the group were exposed to the pathogens. In the field, PRRSV and S. suis 
may spread much more slowly through a group of pigs making it difficult to know 
when exactly to initiate therapy to attain the best overall effect. 
This work and our earlier work6 suggests that treatment with ampicillin, 
penicillin , tiamulin, two different modified live PRRSV vaccines, and an autogenous 
killed S. suis bacterin do not significantly (P<0.05) reduce mortality associated with 
PRRSV/S. suis coinfection. Among the antimicrobials tested to date in this model, 
only ceftiofur hydrochloride has proven to be effective at reducing mortality 
associated with PRRSV/S. suis coinfection. In this study and in an earlier study6, 
the same model and pig source was used to test 8 different protocols. 
In the current study, the interval between ceftiofur treatments was changed 
from 3 consecutive days to every third day for three treatments. This was done in an 
attempt to extend the therapeutic duration of the drug from 3 days to 9 days and 
possibly clear the S. suis infection and eliminate the common problem of 
recrudescence of S. suis-associated disease. Mortality was significantly (P<0.05) 
reduced from 80% in the untreated positive controls to 25% in the ceftiofur treatment 
group (8, 11, and 14 DPI). The every third day regimen appears to be less 
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efficacious than treatment on three consecutive days; however, it is difficult to 
extrapolate and compare results from 2 different experiments. Possible 
explanations for better efficacy of ceftiofur compared to other drugs may be the 
ability of ceftiofur to cross the blood brain barrier, the reduced susceptibility of 
ceftiofur to beta-lactamases 1, and/or better tissue penetration thereby enhancing 
clearance of virulent strains of S . suis from sites such as the joints and serosal 
surfaces. 
Treatment of pigs coinfected with PRRSV and S. suis with ampicillin did not 
significantly (P<0.05) reduce mortality; however, treatment with ampicillin did prolong 
the time between infection with S. suis and the appearance of clinical signs. During 
treatment, few signs of S. suis infection were observed. After treatment was 
discontinued clinical signs similar to those exhibited in the positive controls were 
observed. These observations suggest that S. suis was not effectively cleared from 
the pigs in the ampicillin treatment group. Ampicillin may have worked if treatment 
was continued for a longer duration. This is consistent with reports from practicing 
veterinarians. 
Vaccination with the modified live PRRSV vaccine (Suvaxyn® PRRS) was 
ineffective in reducing mortality. This is consistent with results using a different 
PRRSV vaccine in our earlier study6. Mortality observed in the PRRSV vaccinated 
group in this study was similar to that of the positive controls. The only potential 
benefit of the modified-live PRRSV vaccine was a significant (P<0.05) reduction in 
gross lung lesion scores at necropsy. Previously, it has been suggested that 
vaccination with modified live PRRSV vaccines may exacerbate S. suis-induced 
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disease 10. Experimental results suggest that field and vaccine strains of PRRSV 
may induce damage to pulmonary intravascular macrophages and pulmonary 
alveolar macrophages 10. Based on histories from submissions to the ISU-VDL, 
PRRSV vaccines commonly fail to control, and sometimes exacerbate disease 
associated with PRRSV/S. suis coinfection. 
The reduced dose S. suis exposure was a 1 :100 dilution of the challenge 
inocula. Prechallenge exposure to S. suis significantly (P<0.05) reduced mortality 
associated with PRRSV/S. suis coinfection. This is consistent with other field 
research 13. There was evidence of residual virulence from the reduced dose S. suis 
exposure. Two pigs died from S. suis induced meningitis prior to challenge. Results 
are encouraging enough to merit further work to improve safety and test its ability to 
generate protective immunity to this and other strains of S . suis. 
The high rate of recovery of S. suis from the blood (Table 2) suggests that 
blood may be a better diagnostic sample for veterinarians to obtain than a meningeal 
swab. It is also quicker and minimizes contamination, thereby making it a superior 
sample compared to a meningeal swab. 
In summary, in both this study and a previous study, ceftiofur hydrochloride 
was determined to be the most effective treatment or prevention regimen to reduce 
mortality associated with PRRSV/S. suis coinfection. The results from prechallenge 
exposure to a reduced dose of S. suis warrants further investigation. The S. suis 
isolate will likely need to be attenuated in some way to improve the safety for both 
pigs and personnel administering the product. 
37 
Acknowledgements 
The authors would like to thank Ryan Royer for animal care and monitoring. 
This work was supported in part by Pork Check Off Dollars from the National Pork 
Producers Council and an Iowa Livestock Health Advisory Council grant. 
References 
1. Ahrens FA. Pharmacology Williams and Wilkins. Baltimore, MD. p212 1996. 
2. Amass SF, Clark LK, Wu CC. Source and timing of Streptococcus suis 
infection in neonatal pigs: Implications for early weaning procedures. 
Swine Health and Production 1995;3:189-193. 
3. Devriese LA, Ceyssens K, Hommez J, Kilpper-Balz R, Schleifer KH. 
Characteristics of different Streptococcus suis ecovars and description of a 
simplified identification method. Veterinary Microbiology 1991;26:141-150. 
4. Halbur PG, Paul PS, Frey ML, Landgraf J, Eernisse K, Meng X-J, Lum MA, 
Andrews JJ, Rathje JA. Comparison of the pathogenicity of two U.S. porcine 
reproductive and respiratory syndrome virus isolates with that of the Lelystad 
virus. Veterinary Pathology 1995;32:648-660. 
38 
5. Halbur PG, Paul PS, Meng X-J, Lum MA, Andrews JJ, Rathje JA. Comparative 
pathogenicity of nine US porcine reproductive and respiratory syndrome virus 
(PRRSV) isolates in a five-week-old cesarean-derived, colostrum-deprived 
pig model. Journal Veterinary Diagnostic Investigation 1996;8:11-20. 
6. Halbur PG, Thanawongnuwech R, Brown G, Kinyon J, Roth J, Thacker E, 
Thacker B. Efficacy of antimicrobial treatments and vaccination regimens 
for control of porcine reproductive and respiratory syndrome virus and 
Streptococcus suis coinfection of nursery pigs. Journal of Clinical 
Microbiology 2000;38(3):1156-1160. 
7. Higgins R, Gottschalk M. An update on Streptococcus suis identification. 
Journal Veterinary Diagnostic Investigation 1990;2:249-252. 
8. Meng X-J, Paul PS, Halbur PG, Lum MA. Characterization of a high-virulence 
US isolate of porcine reproductive and respiratory syndrome virus in a 
continuous cell line, ATCC CRL 11171. Journal of Veterinary Diagnostic 
Investigation 1996;8:374-381. 
9. Nelson EA, Christopher-Henning J, Drew T, Wensvoort G, Collins JE, 
Benfield DA. Differentiation of U.S. and European isolates of porcine 
reproductive and respiratory syndrome virus by monoclonal antibodies. 
Journal of Clinical Microbiology 1993;31 :3184-3189. 
39 
10. Thanawongnuwech R, Brown GB, Halbur PG, Roth JA, Royer RL, Thacker BJ. 
Pathogenesis of porcine reproductive and respiratory syndrome virus 
(PRRSV)-induced increased susceptibility to Streptococcus suis infection. 
Veterinary Pathology 2000;37(2):143-52. 
11. Thanawongnuwech R, Halbur PG, Ackermann MR, Thacker EL, Royer RL. 
Effects of low (modified-live virus vaccine) and high (VR-2385)- virulence 
strains of porcine reproductive and respiratory syndrome virus on pulmonary 
clearance of copper particles in pigs. Veterinary Pathology 1998;35:398-406. 
12. Torremorell, M., C. Pijoan, and E. Trigo. Vaccination against Streptococcus suis: 
Effect on nursery mortality. Swine Health and Production 1997;5(4):139-143. 
13. Torremorell M, Pijoan C, Dee S. Experimental exposure of young pigs using a 
pathogenic strain of Streptococcus suis serotype 2 and evaluation of this 
method for disease prevention. Canadian Journal of Veterinary Research 
1999;63:269-275. 
40 
Table 1. Experimental design of vaccination and treatment protocols for control of 
PRRSV and S. suis coinfection. 
Grou~ n Challenge a Treatment Dose & Route Day of Trial 
1 10 PRRS/S.suis No treatment 
2 12 PRRS/S.suis Ceftiofur hydrochloride 5 mg/kg IM 8,11,14 
(Excenel®)b 
3 11 PRRS/S.suis Ampicillin (Polyflex®)c 11 mg/kg 8,9, 10 
4 12 PRRS/S.suis Modified-live PRRSV 2ml IM -14 
vaccine (Suvaxyn® PRRS)c 
5 11 PRRS/S.suis S. suis exposured 2ml IN -12 
{107·2 cfu/ml} 
aPRRSV challenge on day 0, S. suis challenge on day 7 
bPharmacia & Upjohn, Kalamazoo, Michigan, USA 
cFort Dodge Laboratories, Fort Dodge, Iowa, USA 
dThe exposure was a 1:100 dilution of the challenge culture. 
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Figure 1. Percentage of pigs in respective treatment groups surviving over the 
course of the study. 
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Table 2. Number of pigs from which S. suis serotype 2 was recovered from 
blood, CNS (meningeal swab), joint, serosa (pleura, pericardium, peritoneum), 
and bronchoalveolar lavage in the various treatment groups. 
Group Treatment Blood at CNS Joint Serosa BAL a Mean# of 
necroQsy isolations Qer Qig 
1 No treatment 6 A,85 4A 3A 3A 2A 1.8 A,B 
2 Ceftiofur (Excenel®) 3A 2A 2A 1 A 1A 0.75 B 
3 Ampicillin 6A,B 7A 5A 1 A 3A 2:00A 
(Polyflex®) 
4 Mod ified-1 ive 10 B 6A 5A 4A 1 A 2.17 A 
PRRSV 
vaccine (Suvaxyn® 
PRRS) 
5 S. suis ex~osure 2A 2A 2A 1 A OA 0.64 B 
asronchoalveolar lavage 
bWithin each column, values that have the same letter are not significantly 
different (P<0.05). 
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CHAPTER 4. EFFICACY OF THREE NOVEL STREPTOCOCCUS SUIS VACCINE 
CANDIDATES 
A paper submitted to Veterinary Microbiology 
Cameron S. Schmitt, Patrick G. Halbur, James A. Roth, Joann M. Kinyon, 
Ryan L. Royer, Brad Thacker 
Abstract 
Three novel Streptococcus suis (S. suis) vaccine candidates were developed 
in an attempt to reduce clinical disease associated with S. suis induced meningitis 
and septicemia. The three vaccine candidates tested included a ceftiofur-killed 
bacterin, a capsular polysaccharide conjugate vaccine, and a streptomycin-
dependent S. suis mutant. The ceftiofur-killed bacterin was produced by the addition 
of ceftiofur hydrochloride to a mid-log phase culture of S. suis. The capsular 
polysaccharide conjugate vaccine was created by digestion of a culture with 
lysozyme, extraction of the capsular polysaccharide with ethanol, and conjugation to 
tetanus toxoid. The ceftiofur-killed bacterin and the capsular polysaccharide 
conjugate vaccine were adjuvanted in an oil-in-water emulsion. The streptomycin-
dependent S. suis mutant was selected from an N-methyl-N'-nitro-N-
nitrosoguanidine mutated culture and screened for streptomycin-dependent growth. 
The efficacy of these vaccines was compared to that of a commercial killed S. suis 
vaccine (Emulsibac-SS®, MVP Laboratories, Inc., Ralston NE), an autogenous S. 
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suis bacterin (produced by MVP Laboratories, Inc., Ralston NE), and ceftiofur 
hydrochloride injections. 
The vaccines were tested in two experiments in a porcine reproductive and 
respiratory syndrome virus (PRRSV)/S. suis coinfection model. In the first 
experiment 2 doses of each of the vaccines were delivered subcutaneously 28 and 
14 days prior to S. suis challenge. Mortality was 43% (3/7) in the untreated (infected) 
positive controls, 43% (3/7) in pigs treated with ceftiofur hydrochloride injections (5.0 
mg/kg) on 8, 9, and 10 days post infection (DPI), 43% (3/7) in pigs vaccinated with 
an autogenous S. suis bacterin, 57% (4/7) in pigs vaccinated with a commercial 
killed S. suis vaccine, 29% (2/7) in pigs vaccinated with a ceftiofur-killed bacterin, 
43% (3/7) in pigs vaccinated with a capsular polysaccharide conjugate vaccine, and 
57% (4/7) in pigs vaccinated with a streptomycin dependent S. suis mutant. No 
significant differences were observed between groups. In the second experiment, 
the ceftiofur-killed bacterin and the streptomycin dependent S. suis mutant were 
delivered subcutaneously (SQ), intranasally (IN), or both (SQ+IN). Mortality was 
90% (9/10) in the untreated positive controls, 60% (3/5) in pigs vaccinated with a 
ceftiofur-killed bacterin SQ, 50% (5/10) in pigs vaccinated with a ceftiofur-killed 
bacterin SQ and IN, 64% (7/11) in pigs vaccinated with the streptomycin dependent 
S. suis mutant SQ and IN, and 80% (8/10) in pigs vaccinated with the streptomycin 
dependent mutant IN. The ceftiofur killed bacterin showed the greatest reduction in 
mortality of all groups tested and approached a level of significance compared to the 
positive controls (P=0.06). These results are consistent with practitioner reports and 
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field experience and suggest that the efficacy of vaccinating nursery pigs for S. suis 
is limited. 
Introduction 
Streptococcus suis infection is a major cause of septicemia and meningitis in 
neonatal and nursery age pigs 13. Reports of S. suis outbreaks in high health status 
herds indicate that S. suis may lead to high nursery mortality despite aggressive 
intervention strategies 17• It is estimated that 90-100% of all young pigs are colonized 
with S.suis 1. Case submissions to the Iowa State University Veterinary Diagnostic 
Laboratory reveal nearly a 4-fold increase in S. suis cases and an 18-fold increase in 
cases of PRRSV and S. suis coinfection during the last 7 years (Figure 1 ). A 
PRRSV/S. suis coinfection model has been described and mimics the disease 
pattern observed in nursery age pigs and serves as an excellent model for 
evaluating treatment and vaccination protocols for S. suis 15. Use of this model has 
shown that few antimicrobial treatment regimens are efficacious in treating pigs 
coinfected with PRRSV and S. suis10•13. This manuscript discusses vaccine 
development and the results from two trials testing the efficacy of conventional and 
experimental S. suis vaccines in the PRRSV/S. suis coinfection model. 
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Materials and Methods 
Experimental Design 
Two experiments using our PRRSV/S. suis coinfection model15 were 
conducted to compare the efficacy of three different vaccines and their route of 
delivery in reducing mortality and clinical disease associated with PRRSV/S. suis 
coinfection. For each experiment, 10- to 12-day-old crossbred pigs were obtained 
from a herd free of PRRSV and transported to animal isolation facilities at Iowa State 
University. Upon arrival, the pigs were randomly assigned to treatment groups, 
injected with 5.0 mg/kg ceftiofur hydrochloride intramuscularly (IM) once per day for 
the first three days, and allowed to acclimate for one week. An overview of the 
experimental time line is presented in Figure 2. 
In the first experiment, 53 pigs were randomly allocated to 7 groups of 7 pigs 
and 1 group of 4 negative control animals, which were housed in a separate room 
for the duration of the study (Table 1 ). Prior to PRRSV challenge, pigs in group 1-6 
were housed in separate pens in the same room, while pigs in group 7 were housed 
in a separate room due to the potential aerosol spread of the modified live vaccine 
(streptomycin dependent S. suis mutant vaccine). On the day of PRRSV challenge 
(DPI = 0), the pigs were re-grouped so that 1 pig from each treatment group was 
placed in each pen. Pigs in groups 1-7 were challenged intranasally with 5 ml of 
high virulence PRRSV isolate VR-2385 (104·7 TCID50/ml) on day 0 of the study (34-
36 days of age). Seven days after PRRSV challenge (DPI = 7), pigs in groups 1-7 
were challenged intranasally with 2 ml of S. suis serotype 2 (109·3 CFU/ml). Group 1 
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pigs served as the unvaccinated/untreated positive controls. Group 2 was treated 
with 5.0 mg/kg ceftiofur hydrochloride IM on days 8, 9, and 10 DPI. Group 3 was 
vaccinated SQ on -21 and -7 DPI with 2 ml of an autogenous bacterin produced 
from the challenge strain by MVP Laboratories, Inc. (Ralston, NE). Group 4 was 
vaccinated SQ on -21 and -7 DPI with 2 ml of a commercial S. suis vaccine 
produced by MVP Laboratories, Inc. Group 5 was vaccinated SQ on -21 and -7 
DPI with 2 ml of a ceftiofur killed bacterin (described below). Group 6 was 
vaccinated SQ with 2 ml of a capsular polysaccharide conjugate vaccine (described 
below) on -21 and -7 DPI. Group 7 was vaccinated SQ with 2 ml of a streptomycin 
dependent S. suis mutant vaccine (described below) on -21 and -7 DPI. Group 8 
pigs served as unvaccinated/untreated, unchallenged negative controls. Groups 3-7 
were all vaccinated subcutaneously. Vaccines produced by MVP Laboratories, Inc. 
are labeled for intramuscular administration. The extra label use of the commercial 
vaccine and autogenous bacterin was for consistency between all vaccine regimens. 
In the second experiment, 46 pigs were allocated to 5 groups (Table 1 ). Prior 
to PRRSV challenge, pigs in group 1-3 were housed in separate pens in the same 
room, while pigs in groups 4 and 5 were housed in a separate room due to the 
potential aerosol spread of the modified live vaccine in those groups. On the day of 
PRRSV challenge, pigs in groups 1-5 were co-mingled in 6 pens with 7-8 randomly 
assigned pigs so that at least 1 pig per treatment group was placed in each pen. All 
pigs received 5 ml of 105·2 TCID/ml high virulence PRRSV isolate VR-2385 
intranasally at 32-34 days of age on day 0 of the trial and 2 ml of 109·1 CFU/ml S. 
suis type 2 isolate ISU VOL #40634/94 intranasally on day 7 of the trial. Group 1 
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pigs served as unvaccinated/untreated positive controls. Group 2 was vaccinated 
SQ with 2 ml of a ceftiofur killed bacterin (described below) on -21 and -7 DPI. 
Group 3 was vaccinated SQ and IN with 2 ml (each site) of a ceftiofur killed bacterin 
on -21 and -7 DPI. The SQ dose was adjuvanted and the IN dose was not 
adjuvanted. Group 4 was vaccinated SQ and IN with 2 ml (each site) of a 
streptomycin dependent S. suis mutant vaccine (described below) on -21 and -7 
DPI. Group 5 was vaccinated IN with 2 ml of a streptomycin dependent S. suis 
mutant vaccine on -21 and -7 DPI. 
Vaccine preparation 
The ceftiofur killed bacterin was produced by inactivating a mid-log phase 
culture of S . suis in Todd-Hewitt broth (THB) with 0.5 mg/ml ceftiofur hydrochloride 
(Excenel ®, Pharmacia and Upjohn Co., Kalamazoo, Michigan). The mid-log phase 
culture was prepared by plating S. suis isolate ISU-VDL 40634/94 on three blood 
agar plates and incubating for 24 hours at 37°C in 5% C02 . About 100 
colonies/plate were collected and transferred to 6 ml THB and incubated for 2 hours. 
This culture was added to 24 ml warmed THB and incubated for 2 hours. Six ml of 
this culture was added to 94 ml warmed THB and incubated for 3 hours. At the 
completion of the incubation, 50 mg of ceftiofur hydrochloride was added and 
incubation was continued at 37°C for 24 hours. Prior to inactivation, an aliquot was 
tested for purity, culture viability, and concentration . The culture had a concentration 
of 109·0 cfu/ml. After inactivation, the culture was tested for viability by washing a 1 
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ml aliquot with phosphate-buffered saline three times and resuspending in THB. 
This was incubated at 37°C for 48 hours and then plated onto a blood agar plate. 
No growth was evident after 7 days of incubation. The remaining inactivated culture 
was adjuvanted with Montanide ISA 125® (Seppic, Inc. , Paris, France) at a 3:1 
antigen to adjuvant ratio. 
The capsular polysaccharide conjugate vaccine was prepared as described 
previously12. A 2.5:1 capsular polysaccharide to tetanus toxoid ratio was utilized. 
Briefly, capsular polysaccharide from a digest of a 5L culture of S. suis was 
collected and bound covalently to a linking agent (S-acetylthioglycolic acid) and then 
reacted with bromoacetylated tetanus toxoid. The final product was adjuvanted at a 
3:1 antigen to adjuvant ratio in Montanide ISA 125® (Seppic, Inc., Paris, France). 
The streptomycin dependent S. suis mutant vaccine was prepared as 
previously described3. Briefly, a mid-log phase culture was mutated with N-methyl-
N'-nitro-N-nitrosoguanidine and selected for growth on streptomycin containing 
blood agar. Colonies that appeared on the streptomycin agar were then plated on 
blood agar that lacked streptomycin and checked for growth. Those colonies that 
did not grow on standard blood agar were cultivated in Todd-Hewitt broth containing 
100 µg/ml streptomycin and checked for reversion. Reversion to non-streptomycin 
dependence was checked by culture of 0.1 ml of the streptomycin dependent strain 
on each of three blood agar plates and also by culture of 0.1 ml of the streptomycin 
dependent strain in Todd-Hewitt broth without streptomycin for 24 hours and plating 
0.1 ml on each of three blood agar plates. No reversion was observed with the 
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vaccine strain. This mutant was administered as a whole live culture at a 
concentration of 108·7 CFU/ml. 
lnocula Preparation 
PRRS challenge virus isolate VR-2385 was prepared and inoculated as 
previously described10·13 for both experiments. To determine the virus titer of the 
inoculum, VR-2385 was cultured on MARC-145 cells and titrated in a 96-well 
microtiter plate by serial 10-fold dilutions. The challenge inoculum of experiment 1 
had a virus titer of 104·7 TCID50/ml and experiment 2 had a virus titer of 
105·2TCIDso/ml. 
Streptococcus suis serotype 2, isolate ISU-VDL #40634/94, was prepared 
and administered as previously described10·13 . Briefly, the isolate was grown in 
Todd-Hewitt broth (THB) until mid-log phase. A sample of the inoculum was tested 
for purity and concentration. The challenge titer of experiment 1 was 109·3 CFU/ml 
and the challenge titer of experiment 2 was 109·1 CFU/ml. 
Clinical Evaluation 
Clinical respiratory disease scores (range 0-6), clinical lameness scores 
(range 0-3), central nervous system (CNS) scores (range 0-3), and rectal 
temperatures were recorded every other day prior to 0 DPI and daily from 0 DPI until 
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necropsy as previously described10. Pigs found dead did not receive a score for that 
day. 
Necropsy 
Pigs were euthanitized and necropsied when severe lameness or moderate to 
severe CNS disease was first observed. Pigs found dead were necropsied that day. 
At the end of each experiment (28 DPI ), all surviving pigs were euthanitized and 
necropsied. Lungs were scored subjectively for the percent of macroscopically 
visible pneumonia (scores range from 0-100%) as previously described8·9. Routine 
histopathological analysis was done on brain, lung, synovia, lymph nodes, tonsil, 
liver, spleen, kidney, ileum, and nasal turbinate. 
Serology 
Blood samples for serology were collected from all animals upon arrival, at 0 
DPI (the day of PRRSV challenge), 7 DPI, 14 DPI, and 28 DPI , and on any animal 
prior to necropsy if the pig was euthanitized prior to the end of the trial. Serum 
antibody to PRRSV was assayed using Herd Check PRRSV ELISA (IDEXX 
Laboratories, Westbrook, Massachusetts, USA). An S/P ratio of 0.4 or higher was 
considered positive. 
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S. suis Isolation and Identification 
Cultures of whole blood, serosal swabs, meningeal swabs, and joint swabs 
were performed as previously described13. Briefly, swabs were taken during 
necropsy from the serosa (pleura, pericardium, and peritoneum), meninges, and the 
synovia of any inflamed joint and plated onto 5% bovine blood agar plates, chocolate 
agar, and MacConkey's agar. Alpha-hemolytic colonies were Gram stained, tested 
for amylase production, and growth in 6.5% NaCl Brain-Heart Infusion broth4• 
Isolates that were gram positive, produced amylase, and did not grow in 6.5% NaCl 
were serotyped as described previously 11. 
Statistical Analysis 
Fisher's Exact test was used to analyze mortality and organism isolation data 
with P<0.05 used as the level of significance. Clinical scores, and macroscopic and 
microscopic lesion scores were evaluated by analysis of variance (ANOVA) using a 
completely randomized design with the pig as the experimental unit. If the overall 
ANOVA was significant (P<0.05), pair wise comparisons were performed by least 
significant difference. 
Experiment 1 
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Results 
Clinical Evaluation 
Group 1 pigs (untreated positive controls) exhibited lameness, elevated 
rectal temperatures (>40°C), CNS disease, and respiratory distress following S. suis 
challenge. Mortality and clinical signs characteristic of PRRSV/S. suis coinfection 
was first observed at 72 hours post S. suis challenge. Within 120 hours, 2/7 pigs 
exhibited severe CNS disease and were euthanitized. By day 6, all remaining pigs 
in this group were exhibiting mild to severe lameness. Overall mortality in this group 
was 43%. 
Group 2 pigs (ceftiofur hydrochloride treatment on 8, 9, and 10 DPI) exhibited 
mild lameness characteristic of S. suis-induced joint disease in the first week 
following S. suis challenge. Only one pig exhibited severe CNS disease during the 
first week following challenge. Overall mortality, however, was 43%. 
Pigs in group 3, 4, 5, 6, and 7 (MVP autogenous S. suis bacterin, MVP 
commercial S. suis vaccine, ceftiofur killed S. suis bacterin, capsular polysaccharide 
conjugate vaccine, and streptomycin dependent S. suis mutant vaccine, 
respectively) exhibited similar clinical signs and overall mortality as that of the 
positive controls. There were no significant (P>0.05) differences among the test 
groups (groups 1-7) in both clinical score results (rectal temperatures, lameness, 
CNS disease, and respiratory disease scores) and overall mortality. No clinical 
signs or mortality was observed in the negative controls. Mortality was 43, 43, 43, 
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· 57, 29, 43, 57, and 0% in groups 1-8, respectively (Table 1 ). No vaccination regimen 
significantly reduced mortality associated with PRRSV and S. suis coinfection. 
Experiment 2 
Group 1 pigs (untreated positive controls) exhibited lameness, elevated rectal 
temperatures (>40°C), CNS disease, and respiratory distress following S. suis 
challenge. Mortality and clinical signs characteristic of PRRSV/S. suis coinfection 
was first observed at 48 hours post S. suis challenge. Within 120 hours, 5/10 pigs 
exhibited severe CNS disease and were euthanitized. During the remainder of the 
trial there was only one pig in this group that did not exhibit lameness. This was the 
only pig in this group that survived until the end of the trial. Overall mortality in this 
group was 90%. 
Group 2 pigs (ceftiofur killed bacterin SQ) showed a reduction in clinical signs 
including joint/lameness scores and CNS disease scores over the course of the trial 
compared to the positive controls; however, none of the reductions were statistically 
significant. Overall mortality of this group was 60% (P=0.22). 
Group 3 pigs (ceftiofur killed bacterin SQ and IN) showed a numerical 
reduction in clinical signs including joint/lameness scores and CNS disease scores 
when compared to the positive controls; however, none of the reductions were 
statistically significant (p>0.05). Overall mortality of this group was 50% and 
approached a level of significance (P=0.06). 
Group 4 pigs (streptomycin dependent S. suis mutant vaccine SQ and IN) 
showed a reduction in joint/lameness scores and CNS disease scores when 
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compared to the positive controls; however, none of the reductions were statistically 
significant. Overall mortality of this group was 64% (P=0.16). 
Group 5 pigs (streptomycin dependent S. suis mutant vaccine IN) showed a 
reduction in joint/lameness scores and CNS disease scores when compared to the 
positive controls; however, none of the reductions were statistically significant. 
Overall mortality of this group was 80% (P=0.39). 
Gross and Microscopic Lesions 
At necropsy, lungs from all pigs challenged with PRRSV (groups 1-7, 
experiment 1, and groups 1-5, experiment 2) had mottled-tan, non-collapsed 
appearance at necropsy typical of PRRSV infection8. 
Experiment 1 
Groups 1-7 had no significant reductions of mean gross lung lesion scores 
(Table 1 ). 
Experiment 2 
Least significant difference pairwise comparisons of Groups 1-5 mean gross 
lung lesion scores revealed a significant (p<0.05) reduction in gross lung lesions 
compared to the positive controls in Group 2 (ceftiofur killed bacterin SQ). 
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In both experiments, there were no significant differences in incidence or 
severity of microscopic lesions between the groups. All pigs in both experiments 
(excluding the negative controls) had evidence of mild to severe (depending on the 
time of necropsy post PRRSV challenge) proliferative interstitial pneumonia typical 
of PRRSV8·9 . Lesions typical of S. suis infection 15 including fibrinosuppurative 
meningitis, suppurative and histiocytic bronchopneumonia, fibrinosuppurative 
synovitis and bursitis, fibrinous pleuritis, fibrinous pericarditis, and fibrinous 
peritonitis were frequently observed in all groups. 
Bacteriology 
Recovery data of S. suis from both experiments is presented in Table 2. No 
significant differences were found in the number of isolations per group in either 
experiment. No isolations of other bacteria (Actinobacil/us suis or Haemophi/us 
parasuis) that commonly cause polyserositis were made from any pigs. 
Serology 
In both experiments, sera from all pigs had an S/P ratio of less than 0.2 at 0 
DPI and were considered negative for anti-PRRSVantibodies. On day 14 of the trial 
(14 days post PRRSV challenge), sera from all pigs challenged with PRRSV had an 
S/P ratio greater than 0.4 and the negative controls remained negative (S/P< 0.4) 
throughout the study. 
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Discussion 
In general, vaccine development for various Streptococcus sp. has been 
difficult. Only recently has major progress been made against human streptococci 
with the advent of polysaccharide-conjugated vaccines. Factors that influence and 
hinder the progress of streptococcal vaccine development include incomplete 
understanding of virulence factors and mechanisms, poorly immunogenic capsules 
consisting of polysaccharides and inherent difficulties in characterizing these 
molecules, antigenic differences between isolates, interference from passive 
immunity, incomplete immunocompetence at the age of colonization, and others. 
Historically, autogenous and commercially prepared S. suis bacterins and 
vaccines had limited efficacy. Killed bacterins are produced by culturing a pure 
virulent isolate to a certain concentration followed by inactivation with heat or 
formalin treatment. Both of these inactivation methods degrade protein and likely 
disrupt antigenic sites. In this study, the procedure for inactivating S. suis was 
changed to utilize the bactericidal properties of an antimicrobial (ceftiofur) instead of 
heat or formalin in an attempt to conserve antigenic sites that are potentially 
damaged by heat or formalin inactivation. The end product is then adjuvanted with a 
suitable adjuvant for use in food producing animals and injected intramuscularly or 
subcutaneously. The commercial S. suis vaccine and autogenous S. suis bacterin, 
both produced by MVP Laboratories, Inc., were injected subcutaneously, not 
intramuscularly as the label prescribes. This was done for comparison to the novel 
vaccines that were injected subcutaneously. Also, in recent years there has been a 
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push to improve meat quality by giving no injections in muscle. The final product 
was administered intranasally without adjuvant, or was adjuvanted with a standard 
oil-in-water emulsion adjuvant and administered subcutaneously. Mortality data 
from pigs vaccinated SQ+ IN with the ceftiofur killed bacterin in the second 
experiment approached statistical significance (P=0.06). Further improvement in 
efficacy may be obtained through adjusting antigen load, increasing dose, or 
changing adjuvant to obtain different immunological responses. 
Recently published work suggests that PRRSV coinfection with Mycoplasma 
hyopneumoniae interferes with bacterin efficacy14. Similar mechanisms may be at 
work in the PRRSV/S. suis coinfection and may explain the incomplete protection. 
PRRSV is common in nursery age pigs. The interval between vaccination and 
challenge ideally should be increased but is often not possible or predictable in the 
field. Prevention of PRRSV infection in the nursery until the pigs are at least 7-8 
weeks old extends the time available to gain protection from bacterins and vaccines. 
PRRSV has been shown to significantly reduce pulmonary macrophage function 16. 
Perhaps pulmonary macrophages are necessary for a competent response to S. 
suis. Perhaps the ceftiofur killed bacterin is better able to overcome the adverse 
effects of PRRSV reduction in vaccine efficacy. Further design and testing of the 
vaccine is warranted and macrophage-stimulating adjuvants should be evaluated. 
Capsular polysaccharide conjugate vaccines are new to the veterinary 
biologics field. They have been used in humans to prevent neonatal meningitis 
caused by Haemophilus influenzae type b for over a decade5. The FDA approved a 
capsular polysaccharide conjugate vaccine for Streptococcus pneumoniae in 200018. 
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An establishment license has been granted to Aventis Pasteur Inc. to produce a 
meningococcal (Neisseria meningitidis) vaccine 19. Due to the poor ability of human 
neonates to mount an effective immune response to capsular polysaccharides, the 
capsule is isolated and covalently linked to a T cell dependent carrier protein6. 
Incidence of neonatal meningitis due to Haemophilus influenzae has sharply 
declined since the introduction of these vaccines7. Since these striking results have 
been observed in human medicine an attempt to produce a similar vaccine for 
porcine neonatal meningitis was attempted in Experiment 1. Results revealed no 
indications that the vaccine was effective. This failure may have resulted for a 
variety of reasons including interference of maternal antibody, inadequate antigen 
dose, and ineffective conjugation products. Vaccines of this nature are relatively 
expensive. Their efficacy could be improved by including multiple serotypes similar 
to the multivalent pneumococcal vaccines. 
Streptomycin dependent mutant vaccines have been utilized in veterinary 
medicine for a limited number of pathogens. Once PMH® (Bayer Corporation) is a 
product to protect cattle against respiratory disease caused by Pasteurel/a multocida 
and Mannheimia haemo/ytica-induced pneumonia. In this product, both organisms 
are streptomycin dependent. We attempted to mimic the protection gained by this 
modified live product. The streptomycin dependent S. suis mutant may have failed 
due to interference of maternal antibody, inadequate dosage, inadequate 
concentration, inability to replicate in vivo due to inadequate streptomycin supply, 
and others. 
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To date, the only treatment that has consistently and significantly (P<0.05) 
reduced mortality in our PRRSV/S. suis coinfection model is ceftiofur hydrochloride 
(5.0 mg/kg) given IM for three consecutive days post infectio"n with S. suis as 
reported previously10·13. This treatment regimen was included in this study to 
determine if commingling of ceftiofur-treated pigs with untreated pigs would cause 
recrudescence of disease in the ceftiofur treated animals. Results suggest that pigs 
treated with ceftiofur hydrochloride for three consecutive days could be re-exposed 
and suffer similar mortality as to that of the untreated positive controls. Treatment of 
all pigs within a pen or room with ceftiofur appears to be important to prevent 
rebreaks, though no direct comparisons of these methods of treatment were 
conducted in this trial. 
Vaccination of neonates and nursery pigs is problematic in several regards. 
Labor, cost of the products, passive antibody interference, reduced immune 
competency due to immaturity of the immune system, concurrent diseases such as 
PRRS, and stress leading to outbreaks of other diseases need to be considered 
when designing vaccines and vaccination strategies. Recent work suggests that 
vaccination of sows 4 and 1 week pre-farrowing for S. suis using a commercially 
available killed bacterin, significantly reduced CNS signs, microscopic lesions of 
meningitis, and depression in piglets weaned at 13 days of age2. Further work 
needs to be conducted to determine if the vaccines developed in this study could 
stimulate passive protection for piglets. 
61 
Acknowledgements 
The authors would like to thank Dr. Eileen Thacker and Amy Vincent for 
providing the PRRSV challenge inoculum and Pete Thomas for animal care and 
monitoring. This work was supported in part by grants from the Healthy Livestock 
for Iowa Initiative and the National Pork Producers Council. 
References 
1. Amass SF, Clark LK, Wu CC. Source and timing of Streptococcus suis 
infection in neonatal pigs: Implications for early weaning procedures. 
Swine Health and Production 1995;3(5): 189-193. 
2. Amass SF, Stevenson GW, Vyverberg BD, Huxford TW, Knox KE, Grote LA. 
Administration of a homologous bacterin to sows prefarrowing provided 
partial protection against streptococcosis in their weaned pigs. Swine 
Health and Production 2000;8(5):217-219. 
3. Chengappa M, Carter G. Improved Method for Obtaining Streptomycin-
Dependent Mutants from Pasteurella multocida and Pasteurella 
haemolytica, Using N-Methyl-N'-Nitro-N-Nitrosoguanidine. American 
Journal of Veterinary Research 1979;40(3):449-450. 
62 
4. Devriese LA, Ceyssens K, Hommez J, Kilpper-Balz R, Schleifer KH. 
Characteristics of different Streptococcus suis ecovars and description of a 
simplified identification method. Veterinary Microbiology 1991;26:141-150. 
5. Frasch CE, Hiner EE, Gross TP. Haemophilus b disease after vaccination with 
Haemophilus b polysaccharide or conjugate vaccine. American Journal of 
Diseases of Children 1991 ;145(12):1379-1382. 
6. Goldblatt D. Immunisation and the maturation of infant immune responses. 
Developmental Biology Standards 1998;95:125-132. 
7. Goldblatt D. Recent developments in bacterial conjugate vaccines. Journal of 
Medical Microbiology 1998;47(7):563-567. 
8. Halbur PG, Paul PS, Frey ML, Landgraf J, Eernisse K, Meng X-J, Lum MA, 
Andrews JJ, Rathje JA. Comparison of the pathogenicity of two U.S. porcine 
reproductive and respiratory syndrome virus isolates with that of the Lelystad 
virus. Veterinary Pathology 1995;32:648-660. 
9. Halbur PG, Paul PS, Meng X-J, Lum MA, Andrews JJ, Rathje JA. Comparative 
pathogenicity of nine US porcine reproductive and respiratory syndrome virus 
(PRRSV) isolates in a five-week-old cesarean-derived, colostrum-deprived 
pig model. Journal of Veterinary Diagnostic Investigation 1996;8: 11-20. 
63 
10. Halbur PG, Thanawongnuwech R, Brown G, Kinyon J, Roth J, Thacker E, 
Thacker B. Efficacy of antimicrobial treatments and vaccination regimens 
for control of porcine reproductive and respiratory syndrome virus and 
Streptococcus suis coinfection of nursery pigs. Journal of Clinical. 
Microbiology 2000;38(3):1156-1160. 
11. Higgins R, Gottschalk M. An update on Streptococcus suis identification. 
Journal of Veterinary Diagnostic Investigation 1990;2:249-252. 
12. Peeters C, Lagerman P, Weers 0, Oomen L, Hoogerhout P, Beurret M, 
Poelman J. "Polysaccharide-Conjugate Vaccines." in Vaccine Protocols 
Eds. Robinson A, Farrar G, Wiblin N. Humana Press: Totowa, New 
Jersey. 1996. 
13. Schmitt CS, Halbur PG, Roth JA, Kinyon JM, Kasorndorkbua C, Thacker B. 
Influence of ampicillin, ceftiofur, attenuated live PRRSV vaccine, and 
reduced dose Streptococcus suis exposure on disease associated with 
PRRSV and S. suis coinfection. Veterinary Microbiology 2001 ;5;78(1 ):29-
37. 
14. Thacker EL, Thacker BJ, Young TF, Halbur PG. Effect of vaccination on the 
potentiation of porcine reproductive and respiratory syndrome virus 
64 
(PRRSV)-induced pneumonia by Mycoplasma hyopneumoniae. Vaccine 
2000;18(13):1244-52. 
15. Thanawongnuwech R, Brown GB, Halbur PG, Roth JA, Royer RL, Thacker 
BJ. Pathogenesis of porcine reproductive and respiratory syndrome virus 
(PRRSV)-induced increased susceptibility to Streptococcus suis infection. 
Veterinary Pathology 2000;37(2):143-52. 
16. Thanawongnuwech R, Halbur PG, Ackermann MR, Thacker EL, Royer RL. 
Effects of low (modified-live virus vaccine) and high (VR-2385)- virulence 
strains of porcine reproductive and respiratory syndrome virus on 
pulmonary clearance of copper particles in pigs. Veterinary Pathology 
1998;35:398-406. 
17. Torremorell M, Pijoan C. Prolonged persistence of an epidemic 
Streptococcus suis strain in a closed pig population. The Veterinary 
Record 1998;143;394-5. 
18. U.S. Food and Drug Administration. Product Approval Information. 
http://www.fda.gov/cber/efoi/approve.htm April 5, 2001. 
19. U.S. Food and Drug Administration. Licensed Establishments and Products. 
http://www.fda.gov/cber/ep/part3.htm April 5, 2001. 
65 
PRRSV·and S. suis Case Trends at ISU-VDL 1994-2000 
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Table 1. Experimental design and results of vaccination and treatment regimens for 
control of S. suis induced diseasea. 
Gross Lung 
Mean S. suis Lesion 
Groue Treatment Route n Mortal it)'.(%} p value• isolations eer eig Scores 
Experiment 1 
1 Untreated Positive Controls 7 43 a 0.86 b 11.4 b 
2 Ceftiofur Treatment (8, 9, and I Mb 7 43 a 1 b 18.4 b 
10 DPI) 
3 MVP Autogenous Bacterin sac 7 43 a 0.41 0.71 b 18.3 b 
4 MVP Commercial S. suis Vaccine SQ 7 57 a 1.71 b 21.9 b 
5 Ceftiofur Killed Bacterin SQ 7 29 a 0.38 0.43 b 14.9 b 
6 Capsular Polysaccharide Conjugate SQ 7 43 a 0.41 1.29 b 18.1 b 
S. suis Vaccine 
7 Streptomycin Dependent S. suis SQ 7 57 a 1.43 b 27.6 b 
Mutant Vaccine 
8 Negative Controls 4 Oa 0.21 Oa Oa 
Experiment 2 
Untreated Positive Controls 10 90 x 2.30 x 44.0 xy 
2 Ceftiofur Killed Bacterin SQ 5 60 x 0.22 2.20 x 20.2 z 
3 Ceftiofur Killed Bacterin SQ and 10 
I Nd 
50 x 0.06 1.56x 26.2 yz 
4 Streptomycin Dependent S. suis SQ and 11 64 x 0.16 1.72 x 31 .3xyz 
Mutant Vaccine IN 
5 Streptomycin Dependent S. suis IN 10 80 x 0.39 2.50 x 44.5 x 
Mutant Vaccine 
a Values that have the same letter within each column are not significantly different 
(P>0.05) from others in the same experiment 
b Intramuscularly 
c Subcutaneously 
d lntranasally 
* As compared to the untreated positive controls in the same experiment 
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CHAPTER 5. GENERAL CONCLUSIONS 
Summary of Results 
The studies presented in this thesis address treatment and prevention of 
acute infection against S. suis and PRRSV in nursery age pigs in a high morbidity 
and high mortality PRRSV/S. suis coinfection model. This model is used to 
determine the effectiveness of these different treatment and prevention protocols. 
Antimicrobial therapy with ceftiofur hydrochloride (Excenel®) given for three 
consecutive days post S. suis infection or given every third day post S. suis infection 
for three treatments are the only treatments that have successfully reduced mortality 
associated with PRRSV/S. suis coinfection. Treatment with ampicillin for three 
consecutive days post S. suis infection failed to significantly reduce mortality 
associated with PRRSV/S. suis coinfection in our model. Previous work has also 
shown other commonly used treatments have failed to significantly reduce mortality 
associated with PRRSV/S. suis coinfection2·3. Those treatments included: procaine 
penicillin G for three consecutive days post S. suis infection and tiamulin given per 
os in drinking water for three days post S. suis infection. 
Considerable research has been conducted to create a successful method to 
prevent mortality associated with PRRSV/S. suis coinfection. Vaccines to date do 
not provide complete protection against S. suis or PRRSV. In this work and in 
previous work2·3, two commercial PRRSV vaccines have failed to prevent mortality 
associated with PRRSV/S. suis coinfection. 
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In chapter 2 it was shown that a significant reduction in mortality was induced 
by exposing pigs prior to PRRSV challenge to a reduced dose S. suis exposure. 
There was however, residual virulence associated with this prevention measure. 
Others have also observed similar results by exposing nursery pigs to virulent 
isolates of S. suis4 . A vaccine based on reduced dose exposure to virulent S. suis 
would not be practical due to S. suis' zoonotic potential and the residual virulence 
observed. Modified live vaccines are becoming increasingly common in the swine 
industry. Modified live vaccines against Salmonella choleraesuis, Lawsonia 
intracel/ularis, and Actinobacillus pleuropneumoniae are now available commercially. 
In chapter 3, a reduction in mortality (p=0.06) observed when nursery pigs 
were vaccinated with a ceftiofur killed bacterin intranasally and intramuscularly, but 
this did not reach a significant (p<0.05) level. Vaccines that failed to induce any 
observable reduction in clinical signs, gross and microscopic lesions, and mortality 
included a capsular polysaccharide conjugate vaccine and a streptomycin 
dependent mutant of the parent strain. 
Many reasons may contribute to the difficulty of generating an adequate 
immune response in neonatal and nursery age pigs including: maternal antibody 
interference, limited immunocompetency due to the pigs' age, inadequate antigen 
load in the vaccine, and improper adjuvant. Complicating factors in field settings 
include in utero or neonatal PRRSV exposure, from concurrent virus interference or 
bacterial infection, high stocking densities, poor ventilation and pig comfort, and 
other stressors that decrease the functional ability of the neonates' and nursery age 
pigs' immune system. 
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Different techniques that have been used to reduce or eliminate S. suis 
exposure at a young age have failed. Segregated early weaning, medicated early 
weaning, and modified medicated early weaning protocols have not reduced the 
incidence of S. suis in modern swine production 1• In fact, these techniques may 
have exacerbated the problem by reducing other swine flora that would develop in 
non-intensive swine rearing operations. As described in the literature review, the 
incidence of S. suis cases and the number of PRRSV/S. suis coinfection cases have 
dramatically increased since the early 1990's when confinement operations became 
the norm in modern swine production. Other factors may be responsible for this 
increased incidence including: better diagnostic techniques and increased 
knowledge of the pathogens. More research on a better vaccine is clearly needed. 
Recommendations for Future Research 
Future research is needed to elucidate the host's response to vaccination and 
treatment protocols. Immunology in neonatal and nursery aged pigs is in its infancy 
and needs to be expanded. Vaccine research should be based on knowledge of 
species specific research. Also, a more detailed view of the pathogenesis of the 
organism and its interaction with PRRSV may give specific clues of different areas to 
target for protection. 
Continuation of this work should include determination of adequate antigen 
load in the ceftiofur killed bacterin to possibly provide a more effective immune 
response, the use of adjuvants that target specific immune responses, testing of a 
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hemolysin-negative mutant strain of S. suis, and other new ideas such as a vaccine 
that uses MRP and EF as antigen5. The use of a streptomycin dependent mutant 
vaccine in pigs primed with high enough systemic streptomycin levels to allow the 
mutant to flourish for a period of time and then withdrawing the antimicrobial could 
be attempted, though dependence on another antimicrobial may be indicated due to 
the long withdrawal time necessary for aminoglycoside antibiotics. Also, testing the 
protection of the ceftiofur killed bacterin against challenge with heterologous strains 
of S. suis serotype 2 and other serotypes. A live, avirulent mutant S. suis capable of 
replication in vivo may provide an improved immune response. 
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